Clazosentan

Base Information

• Chemical Name: Clazosentan
• CAS No.: 180384-56-9
• Molecular Formula: C25H23N9O6S
• Molecular Weight: 577.5718
• UNII: 3DRR0X4728
• DSSTox Substance ID: DTXSID60170955
• Nikkaji Number: J915.266K
• Wikipedia: Clazosentan
• Wikidata: Q1099339
• NCI Thesaurus Code: C79486
• Pharos Ligand ID: 57UX9CQ4NMY7
• Metabolomics Workbench ID: 149893
• ChEMBL ID: CHEMBL109648
• Mol file: 180384-56-9.mol

Synonyms:AXV 034;AXV 343434;AXV-034;AXV-034343;AXV-343434;AXV343434;clazosentan;Ro 61-1790;Ro-61-1790;VML 588;VML-588;VML588

Chemical Property of Clazosentan

Chemical Property:

• Vapor Pressure: 6.34E-24mmHg at 25°C
• Melting Point: 239-241°
• Boiling Point: 754.5°Cat760mmHg
• PKA: 2.97±0.10(Predicted)
• Flash Point: 410.1°C
• PSA: 208.49000
• Density: 1.485g/cm³
• LogP: 3.54870
• XLogP3: 1.6
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 11
• Exact Mass: 577.14920066
• Heavy Atom Count: 41
• Complexity: 917

Purity/Quality:

99% ^*data from raw suppliers

Clazosentan ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
• Recent ClinicalTrials: Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
• Recent EU Clinical Trials: A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH)
• Recent NIPH Clinical Trials: A double-blind study to assess the efficacy and safety of clazosentan in reducing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling
• Uses: Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury.